Description du projet
Un outil de point de service révolutionnaire pour la détection des coronavirus
La pandémie actuelle de COVID-19 a mis en évidence le manque de préparation des gouvernements, des organisations publiques et des communautés à faire face et gérer une telle crise sanitaire. Pour de nombreuses maladies infectieuses, une détection rapide des agents pathogènes est essentielle pour prendre les mesures de confinement appropriées pour endiguer leur propagation. Le projet CoNVat, financé par l’UE, a pour objectif de développer une approche de biocapteur au point de service pour l’identification directe, rapide et spécifique du nouveau coronavirus, directement dans l’échantillon du patient. La technologie générée pourra différencier les différentes souches virales et être mise en œuvre dans des environnements décentralisés pour améliorer le diagnostic précoce, la surveillance et la prise en charge clinique des patients.
Objectif
The recent outbreak in China caused by the emerging nCoV virus is challenging the level of global readiness from governments, public organizations and community to face and manage both its social and health consequences. Once the emergence is recognized and identified, it is crucial to initiate the necessary measures to prevent the spread. This involves therapeutics, vaccines, and devising efficient, fast, readily accessible diagnostics methods that specifically confirm the presence of the virus. Early detection can allow the rapid implementation of containment measures, which are the key to reduce the risk of amplification. The aim of CoNVat is to implement a Point-of-care label free biosensor for the direct, fast and specific identification of nCoV in decentralized settings to improve its early diagnosis and the clinical management of patients. The approach employs an already developed technology based on nanophotonic bimodal waveguide (BiMW) interferometers capable of providing real time, highly sensitive detections assays in short sample turnaround times. We propose two different strategies: (i) the development of a fast antigen-based diagnostic test for the specific detection of the intact virus in patient’s samples such as respiratory specimens and non-respiratory fluids (serum, urine…) to be deployed to clinical settings for initial screening and (ii) development of a multiplexed molecular test, PCR-free, for the reliable identification of nCoV, being possible to differentiate the type and strain of coronavirus form other related or more common respiratory viruses. This latter strategy will provide a disruptive diagnostic tool not only from a clinical perspective to improve patient’s outcome but also for surveillance, to study and understand possible transmission routes of this virus by analysing samples from animal reservoirs. Final prototype validation will demonstrate the potential of this approach for the management of future infectious outbreaks.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
08193 Cerdanyola Del Valles
Espagne